Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
Holding AGEN?
Track your performance easily
AGEN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.50 - $19.69
Previous Close$2.75
Volume420.45K
Average Volume (3M)493.29K
Market Cap
$64.51M
Enterprise Value$111.25M
Total Cash (Recent Filing)$44.78M
Total Debt (Recent Filing)$70.99M
Price to Earnings (P/E)―
Beta3.70
Next Earnings
Mar 13, 2025EPS Estimate
-$2.64Last Dividend Ex-Date
Apr 26, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-11.00
Shares Outstanding23,458,929
10 Day Avg. Volume462,545
30 Day Avg. Volume493,290
Standard Deviation0.20
R-Squared0.11
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-0.22
Price to Sales (P/S)0.40
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.69
Enterprise Value/Gross Profit-1.37
Enterprise Value/Ebitda-0.64
Forecast
1Y Price Target
$8.50Price Target Upside215.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Agenus News
PremiumCompany Announcements
Agenus Secures $22M Mortgage to Advance Cancer Treatment
PremiumCompany Announcements
Agenus Inc. Reports Progress in Immunotherapy Development
Bulls Say, Bears Say
Bulls Say
Clinical Progress And Regulatory AgreementsThe EMA has agreed on dose selection and trial design for the Phase 3 trial, which is a significant step forward for the company's clinical progress.
Efficacy And Treatment PotentialSignificant tumor reductions from the Bot/Bal therapy could minimize disease recurrence and reduce the need for invasive procedures in colon cancer patients.
Strategic Realignment And Cost ReductionAgenus announced a strategic operational realignment plan to refine its focus on botensilimab/balstilimab (bot/bal) in MSS colorectal cancer (CRC), while also initiating plans to significantly reduce operating costs.
Bears Say
EarningsIn the quarter, Agenus recorded $25.1M in other revenues and a net loss of $67.2M.
Financial PerformanceThe company's cash runway seems to not extend beyond two quarters, which is a key driver of a significant sell-off.
Regulatory ChallengesThe FDA's advisement against the accelerated approval path is a negative in terms of the time and cost to market.
---
Ownership Overview
11.80% Insiders
17.65% Mutual Funds
4.79% Other Institutional Investors
55.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $2.50 and its highest was $19.69 in the past 12 months.
What is Agenus’s market cap?
Currently, no data Available
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Mar 13, 2025 which is in 72 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Nov 12, 2024. The company reported -$3.08 earnings per share for the quarter, missing the consensus estimate of -$2.314 by -$0.766.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus pays a Notavailable dividend of $0.6 which represents an annual dividend yield of N/A. See more information on Agenus dividends here
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -$2.64.
How many shares outstanding does Agenus have?
Agenus has 23,458,930 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of -$3.08 in its last earnings report, missing expectations of -$2.314. Following the earnings report the stock price went down -20.513%.
Which hedge fund is a major shareholder of Agenus?
Among the largest hedge funds holding Agenus’s share is Oracle Investment Management Inc. It holds Agenus’s shares valued at N/A.
---
Agenus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (215.99% Upside)
$8.50 (215.99% Upside)
Blogger Sentiment
Bullish
AGEN Sentiment 85%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 127.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.91%
Trailing 12-Months
Company Description
Agenus
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
---
AGEN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of promising advancements in therapy development and strategic initiatives to bolster financial stability, but also highlighted ongoing financial constraints and increased net loss. While the potential of BOT/BAL is noteworthy, the financial challenges are significant.Read More>---
AGEN Stock 12 Month Forecast
Average Price Target
$8.50
▲(215.99% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Fate Therapeutics
―
MacroGenics
―
Karyopharm Therapeutics
―
Best Analysts Covering AGEN
1 Year
1 Year Success Rate
2/32 ratings generated profit
1 Year Average Return
-52.61%
reiterated a buy rating last month
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 6.25% of your transactions generating a profit, with an average return of -52.61% per trade.
---